The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Dealing with Simultaneous Cancer & Rheumatic Disease

Dealing with Simultaneous Cancer & Rheumatic Disease

March 17, 2018 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Cancer cells

Cancer cells

SAN DIEGO—New insights into how scleroderma and myositis may be linked with cancer have led to intriguing questions that could impact patient care, experts said at the 2017 ACR/ARHP Annual Meeting in November.

You Might Also Like
  • Complex Treatment: Cancer, Immunotherapy & Rheumatic Disease
  • Study Assesses Immune Checkpoint Inhibitors Safety in Rheumatic Disease
  • Immune-Related Adverse Events with Use of Checkpoint Inhibitors for Immunotherapy of Cancer
Explore This Issue
March 2018
Also By This Author
  • Key Findings in Basic Science This Year Hold Promise for Potential Rheumatology Therapies

Understanding the relationship between cancer and rheumatic diseases is important because rheumatologists are seeing more and more patients with both diseases, and treating both conditions at the same time poses a challenge, said Ami Shah, MD, MHS, director of clinical and translational research at the Johns Hopkins Scleroderma Center in Baltimore.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Researchers have found that scleroderma patients with anti-RNA polymerase-3 (POL3) or anti-RNPC-3 antibodies, and myositis patients with TIF1-gamma or NXP-2 antibodies, are more likely to develop cancer right around the time of the onset of their rheumatic disease. And evidence has emerged that naturally occurring anti-tumor immune responses directed at altered auto­antigens in cancers may spread, possibly giving rise to these autoimmune disorders.

Antibody subsets can help define a patient’s cancer risk, Dr. Shah said. For example, she and her colleagues found that relative to patients with anti-centromere antibodies, scleroderma patients with anti-POL3 or anti-RNPC3 antibodies carried a fourfold risk of developing cancer within a short interval of scleroderma onset.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In other research, among 213 dermatomyositis patients assessed at Hopkins and Stanford University, 83% of those with cancer-associated dermatomyositis were identified by anti-NXP-2 or anti-TIF-1-gamma antibodies.

But many questions remain, Dr. Shah said.

“Is aggressive cancer screening warranted in these patients, and does early cancer detection improve both cancer and rheumatic disease outcomes?” she said. So far, we don’t have much hard data to answer this.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Can Cancer Treatment Affect Autoimmune Disease?

In one intriguing case recently published, a 43-year-old woman with diffuse scleroderma and polymyositis overlap with anti-PM/Scl antibodies, was found to have a solid pseudo­papillary pancreatic neoplasm. When the cancer was resected—she didn’t receive chemo­therapy—she was quickly weaned off immunosuppression, and her skin thickening and myositis resolved.

“If rheumatic diseases may be a manifestation of an underlying cancer, could cancer therapies [treat] rheumatic disease?” she asked. “I think at the end of the day, this is the question we all really care about.”

The session also covered the challenges and risks of using immune checkpoint inhibitors with autoimmune diseases. The growing use of immune checkpoint inhibitors (ICIs) for all types of cancer poses a particular challenge for rheumatologists, said Laura Cappelli, MD, MHS, assistant professor of medicine at the Johns Hopkins Arthritis Center in Baltimore, Md. The drugs work by blocking negative costimulatory molecules—essentially, “taking away the stop light,” she said—and boosting T cell activation. There are six FDA-approved ICIs, with even more tumor types, drugs and combinations likely to enter the fray.

Pages: 1 2 3 | Single Page

Filed Under: Meeting Reports, Scleroderma Tagged With: ACR/ARHP Annual MeetingIssue: March 2018

You Might Also Like:
  • Complex Treatment: Cancer, Immunotherapy & Rheumatic Disease
  • Study Assesses Immune Checkpoint Inhibitors Safety in Rheumatic Disease
  • Immune-Related Adverse Events with Use of Checkpoint Inhibitors for Immunotherapy of Cancer
  • The Latest Data on Cancer Immunotherapy’s Interaction with Autoimmunity

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)